Table 1

BALF cell counts in 7 horses with IAD before and after treatment with corticosteroids.

Lymphocytes (%)

Macrophages (%)

Neutrophils (%)

Mast cells (%)

Eosinophils (%)

Total Cell Count (cells/mm3)


Dexamethasone

Day 1

Horse 1

56.17

29.14

13.84

0.36

0.18

298.9

Horse 2

53.35

27.02

17.78

1.85

0.00

441.1

Horse 3

30.09

62.39

5.69

1.65

0.18

150.0

Horse 4

45.49

30.45

3.95

3.95

0.00

113.3

Horse 5

68.09

9.98

21.03

0.98

0.00

231.1

Horse 6

56.83

21.39

17.82

1.98

0.00

142.2

Horse 7

66.52

21.23

10.94

1.31

0.00

122.2


Mean ± SEM

53.79 ± 4.91 *

28.80 ± 6.17

13.01 ± 2.44

1.73 ± 0.43

0.05 ± 0.01

214.1 ± 45.5

Day 15

Horse 1

52.74

16.44

29.45

1.37

0.00

212.2

Horse 2

17.01

78.07

4.30

0.20

0.20

1026.7

Horse 3

22.12

62.82

15.06

0.00

0.00

204.4

Horse 4

40.72

13.80

40.50

4.75

0.00

90

Horse 5

48.16

1.64

46.72

3.48

0.00

162.2

Horse 6

52.21

15.50

32.10

0.18

0.00

35.6

Horse 7

56.30

30.87

12.17

0.65

0.00

110


Mean ± SEM

41.32 ± 5.94 *

31.31 ± 10.73

25.76 ± 5.92

1.52 ± 0.71

0.03 ± 0.01

263.0 ± 129.5


Fluticasone Day 1

Horse 1

66.42

13.18

20.40

0.00

0.00

246.7

Horse 2

75.55

7.64

14.30

2.51

0.00

378.9

Horse 3

60.68

11.14

17.50

10.45

0.23

42.2

Horse 4

54.39

6.34

35.12

4.15

0.00

104.4

Horse 5

54.84

14.75

19.12

11.29

0.00

167.8

Horse 6

67.00

5.30

24.60

3.30

0.00

48.9

Horse 7

58.50

20.70

19.60

1.10

0.00

93.3


Mean ± SEM

62.48 ± 2.89

11.29 ± 2.06

21.52 ± 2.55

4.69 ± 1.68

0.03 ± 0.01

154.6 ± 46.0

Day 15

Horse 1

69.34

8.42

21.84

0.40

0.00

156.7

Horse 2

45.35

45.35

7.88

1.41

0.00

143.3

Horse 3

62.71

14.29

22.76

0.24

0.00

123.3

Horse 4

58.33

14.47

23.90

3.07

0.22

133.3

Horse 5

40.04

47.00

10.83

2.13

0.00

n/a

Horse 6

60.60

1.10

36.00

1.90

0.40

20.1

Horse 7

66.40

9.10

23.00

1.50

0.00

56.7


Mean ± SEM

57.54 ± 4.11

19.96 ± 6.98

20.89 ± 3.51

1.52 ± 0.37

0.09 ± 0.02

105.6 ± 22.2


* indicates a significant difference between pre- and post- treatment (p < 0.05).

Beekman et al. BMC Molecular Biology 2011 12:5   doi:10.1186/1471-2199-12-5

Open Data